Transmission ways

I. Airborne droplets

This way has been proven. When a patient sneezes, coughs, and even talks, microdrops are formed that contain the virus, and these microdrops can enter the mucous membranes of a healthy person and lead to the development of a coronavirus infection. Microdroplets can serve as a source of infection not only due to getting into the respiratory tract, but also on the mucous membrane of the eye. Therefore, medical personnel and representatives of other professions in contact with a large number of people should protect themselves by wearing both a mask and transparent glasses (or a shield that protects the eyes).

It is important that in many people, coronavirus infection is not very symptomatic (a slight increase in temperature, slight catarrhal symptoms [runny nose, nasal congestion, rare and mild cough]. Such people, even without knowing it, can be a source of infection for others. Therefore, non-specific preventive measures are important during an epidemic, including a decrease in personal interaction with people. A number of cases of infection are associated with being in medical institutions (as sick people can go to them), so their visit should be minimized.

Practical findings

1. It is necessary to reduce the possibility of contact with other people during the epidemic. That is, do not use public transport, do not go to crowded places (museums, concerts, bars, restaurants, cinema, etc.).
2. A visit to medical institutions (clinics, hospitals, dentists) should be excluded, if possible, if the situation allows it.
3. The issue of wearing masks depends on the situation.
   If a person is healthy , and he has no symptoms of respiratory tract infection and temperature, then the main task is to protect yourself from infection. However, WHO does not recommend wearing a medical mask to healthy people to protect against infection.. , , . , . , (. ), . , , – . – , . 6 , , .
   – , . – . .
   , – ( ) . – – , . . , , – , .
   ( , , ..) — , . , , , — .
4. 1,5-2 , .
5. (, .) – . , , – .
6. – , ( , , ), – , . . . , .
7. , – , .

II. -

, , « ». .

1. , . , , . , .
2. , , .
3. , . .. , 1,5 – . – .

III.

, , . , , , .

1. , .
2. .
3. .
4. , .
5. , .
6. . .

, , , , , , 4 9 . : 62-71% , 0,5% , 0,1% , 0,23% . 0,7% 2-10 . , 0,05-0,2% 0,02% - . 40% () .

, — . — , . .

1. , ( ) .
2. , , – (, ) , (, , ) – .
3. .
4. – , .

– .. . 15 .

5-6 , 14 , 24 .

, 81% ( , – , , . ), 14% ( ), 5% ( ).

, , , , ( ).

, 60 .

( 37,3 ), , , 10% . , .

20 ( 17 24 , 37 ). , — .

. 48 .

, ( ) . , . , . . , – . , – . .

, 14 . , 14 .

, .

. 80  , , .

– , , – , ..

1. ( )

, , , .. , , , . , , .

(.. 1,5-2 ) .

2.

, , . . , , , .

– , . , , 1,5-2 .

– . , , , — .

3.

, , , , . . , . , .
. , . . – .

– . , . , – . , . . . .

1. , , , , . .
   – , , , , , , , , .
2. , .
3. .

, . , , . , . , , . , , « » — , . , . . , , , . , – . , . (, , .) , 1,5-2 . - . ( , ) . , - . , , -. – , , – . , . , , . , , , – , , .

• : : Covid-19

• 
  ( , , , ) ( , ).
• Coronavirus disease 2019 (covid-19): a guide for UK General Practitioners (BMJ)
  ( ).
• COVID-19—New Insights on a Rapidly Changing Epidemic (JAMA)
  2 .
• Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing (JAMA)
  ( ) .
• Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy (JAMA)
  .
• The psychological impact of quarantine and how to reduce it: rapid review of the evidence (Lancet)
• All medical journals have opened full-text free access to published coronavirus material. Here are just a few selections: BMJ , Lancet , JAMA , NEJM , Cell , Science , Nature .